20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T20967 | Methyltetrazine-Amine | Methyltetrazine amine | PROTACs |
Methyltetrazine-Amine is a methyl-substituted tetrazine amine used in the synthesis of PROTAC molecules. | |||
T17397 | Amine-PEG-CH2COOH (MW 2000) | Amine-PEG-CH2COOH (MW 5000) | Others , PROTAC Linker |
Amine-PEG-CH2COOH (MW 2000) is a PEG-based PROTAC linker that can be used in PROTAC synthesis. | |||
T23535L | Xanthine amine congener trihydrochloride | Xanthine amine congener trihydrochloride (96865-92-8 Free base) | Adenosine Receptor |
Xanthine amine congener trihydrochloride is a potent adenosine antagonist that reverses the reduction in urine flow, sodium excretion and heart rate produced by the adenosine agonist, N6-cyclohexyladenosine. | |||
TP1545L1 | FFAGLDD amine salt | Others | |
FFAGLDD amine salt is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release. | |||
T36020 | Florfenicol amine (hydrochloride) | ||
Florfenicol amine is a major metabolite of the antibiotic florfenicol, a fluorinated derivative of chloramphenicol that is commonly used in veterinary medicine. The pharmacokinetics of florfenicol and florfenicol amine a... | |||
T14220 | Amine-PEG3-Biotin | Others | |
Amine-PEG3-Biotin can be used as a signal amplification label. | |||
T15839 | M-PEG12-amine | Others | |
m-PEG12-amine is a PEG-based PROTAC linker and a non-cleavable 12 unit PEG ADC linker employed in the synthesis of PROTACs[1] and antibody-drug conjugates (ADCs)[2]. | |||
T14250 | Amino-PEG8-amine | Others | |
Amino-PEG8-amine is a pegylated based PROTAC linker that can be used in the synthesis of PROTACs. It is a conjugate PEG derivative containing two amino (NH2) groups. | |||
T15058 | DBCO-amine | ||
DBCO-amine is a cleavable ADC linker used in antibody-drug conjugates (ADCs) synthesis[1]. | |||
T17411 | Amino-PEG13-amine | H2N-PEG13-CH2CH2NH2 | Others , PROTAC Linker |
Amino-PEG13-amine (H2N-PEG13-CH2CH2NH2) is a PEG-based PROTAC linker that can be used in PROTAC synthesis. | |||
T14226 | Amino-PEG11-amine | Others , PROTAC Linker | |
Amino-PEG11-amine, a polyethylene glycol (PEG)-based linker with 12 units, facilitates the conjugation of two mono diethylstilbestrol (DES)-based ligands. This strategy enhances the preparation of selective and potent es... | |||
T35478 | Cis VH 032, amine dihydrochloride | (S,S,S)-AHPC | |
cis VH 032, amine dihydrochloride ((S,S,S)-AHPC) is a negative control for the functionalized VHL ligand VH 032, amine . | |||
T50052 | 1,2-diphenylpropan-2-amine | Others | |
1,2-Diphenylpropan-2-amine is the monohydrochloride metabolite of the (S,R)-isomer of Remacemide.1,2-Diphenylpropan-2-amine has anticonvulsant properties. | |||
T19507 | Perfluamine | FTPA,Tris(perfluoropropyl)amine,Perfluorotripropylamine | Others |
Perfluamine (FTPA) is a hydrophobic carrier fluid and can be used as a blood substitute. | |||
T0565 | Bis(2-chloroethyl)amine hydrochloride | Others | |
Bis(2-chloroethyl)amine hydrochloride is used as pharmaceutical intermediate. | |||
T0533 | N-Aminopiperidine hydrochloride | Piperidin-1-amine hydrochloride | Others |
N-Aminopiperidine hydrochloride (Piperidin-1-amine hydrochloride) is a metabolite (M1) of the canabinoid receptor 1 antagonist Rimonabant, an antiobesity agent. | |||
T7683 | Adenosine amine congener | ADAC | Adenosine Receptor |
Adenosine amine congener (ADAC) (ADAC) is an agonist of selective A1 adenosine receptor,. | |||
T17668 | Boc-NH-PEG12-NH2 | NHBoc-PEG12-amine | Others , PROTAC Linker |
Boc-NH-PEG12-NH2 (NHBoc-PEG12-amine) is a PEG-based PROTAC linker that can be used in PROTAC synthesis. | |||
T17407 | Amino-PEG12-amine | H2N-PEG12-CH2CH2NH2,PEODA13 | Others , PROTAC Linker |
Amino-PEG12-amine (H2N-PEG12-CH2CH2NH2) is a PEG-based PROTAC linker that can be used in PROTAC synthesis. | |||
T13601 | CDD3506 | 1-TRITYL-1H-IMIDAZOL-4-AMINE | P450 |
CDD3506 (1-TRITYL-1H-IMIDAZOL-4-AMINE) increases high-density lipoprotein cholesterol by targeting hepatic CYP3A. |